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Abstract 
Antimicrobial resistance is a growing problem in this era. Resistance to the majority of clinical 
antibiotics including those of a ‘last line of defence’ nature has been seen in a number of 
laboratory and clinical settings. One method aiming at reducing this problem is altering 
existing antimicrobial compounds, in order to improve pharmacological effects (avoiding 
resistance mechanisms, improved spectrum of use). Analysis of the interactions between the 
antimicrobial compounds and their targets can determine whether modifications to current 
antimicrobials (such as moenomycin A, a glycosyltransferase inhibitor) have altered the 
mode of action.  
ecoPBP1B is a bifunctional glycosyltransferase that could be used as a model for beta lactams 
and moenomycins, aiding in the design and development of novel antimicrobials based on 
these families. Moenomycin A has not seen high clinical usage due to poor pharmacokinetics 
and bioavailability. This project aimed to show whether ecoPBP1b can be used as a model 
for novel antimicrobials, such as seeing whether Moenomycin A analogues (with cell 
penetrating peptides to facilitate entry into the bacterial cell) still retain their ability to bind 
to glycosyltransferases. In addition, this project looked at whether different beta-lactams 
would significantly alter the conformation of the transpeptidase domain of ecoPBP1b. 
Building on previous studies into ecoPBP1b, we managed to successfully produce usable 
quantities of ecoPBP1b for crystallisation in conjunction with a variety of ligands. Crystals 
were produced potentially containing complexes including such compounds as AI167-p and 
AI168-p (Moenomycin A analogues), cefotaxime, cephradine, and a novel beta-lactamase 
inhibitor (CW-019). 
3D structures of ecoPBP1b in complex with AI167 were produced, successfully showing the 
Moenomycin A analogue bound into the transglycosylase active site. This showed that the 
addition of peptides to the moenomycin molecule has not interfered with the interactions 
required for the compound to bind to the transglycosylase domain. In addition, ecoPBP1b 
was co-crystallised with ampicillin bound to the penicillin binding region, which is consistent 
with previous studies. 
There are issues that need to be addressed with regards to ecoPBP1b before it can be used 
as a reliable model, especially with beta-lactams. However, the main project goal (using 
ecoPBP1b for novel MoeA analogues) has been achieved, as well as furthering insights into 
crystallisation of proteins in general.  
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“Any true wizard, faced with a sign like 'Do not open this door. Really. We mean it. We're 
 not kidding. Opening this door will mean the end of the universe,' would automatically  
open the door in order to see what all the fuss is about.” 
 
                                                                                          ― Terry Pratchett (The Last Continent) 
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1. Introduction  
1.1. Antimicrobial Crisis 
Antibiotics have been widely used as a clinical treatment since the introduction of 
sulphonamides in 1937 (Davies & Davies, 2010, West & Coburn, 1940). Whilst antibiotics 
revolutionised modern medicine, and dramatically improved the quality of life for millions 
around the globe (from allowing the performing of invasive surgical procedures through to 
the introduction of chemotherapy treatments), the cost of these advancements has not been 
seen as severe until recently (Brown and Wright, 2016). Many of the antibiotics and 
antimicrobials discovered in the 20th century have had resistance mechanisms develop in 
previously susceptible bacterial species, and a large proportion are now no longer in regular 
use due to widespread resistance to their mode of action (Blair et al., 2014).  
The need for novel antimicrobial compounds has been considered a worldwide public health 
concern for decades now (World Health Organisation, 2014). Antimicrobial resistance has 
been recorded as early as the 1930s, and one of the most widely used antimicrobial 
compound groups (penicillins) has had mechanisms of resistance identified from 1940 
(Abraham & Chain, 1940; Davies & Davies, 2010). This has led to a severe reduction in the 
number of functional antimicrobial compounds suitable for commercial and medical use. 
Reductions in funding has been put towards novel antimicrobial research by pharmaceutical 
companies in recent years, due to the poor economic return on investments in this area 
(Payne et al., 2007). As such, few notable discoveries have been made in the last few decades 
(Arias and Murray, 2015).  
1.2.  Current Antimicrobials 
The majority of antimicrobials that have been licensed for use are derived from bacterial and 
fungal products (Brown and Wright, 2016). Such natural antibiotic products were discovered 
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in the so-called ‘Golden Age’ of antibiotics, between 1940 and 1962 (Singh and Barrett, 
2006). These antimicrobial compounds have a variety of targets, as shown by table 1.  Beta-
lactams inhibit cell wall growth by binding to major peptidoglycan synthesising enzymes, 
tetracyclines target the 30s subunit of ribosomes and prevent protein synthesis, and 
quinolones have shown the ability to prevent growth via the inhibition of the DNA synthetic 
enzymes DNA gyrase and topoisomerase (Cheng et al., 2013., Singh and Barrett, 2006). The 
antibiotics currently in use have been heavily modified, as many of the 1st generation 
compounds of such antibiotic groups have been shown to have clinical resistance develop 
after large-scale use. This can be clearly seen in the Beta-lactam families, with the 
development of the later families of cephalosporins, and methicillins (Singh and Barrett,  
2006). 
CLASS/SUBCLASS AREA OF EFFECT PRIMARY TARGET WHO 
CLASSIFIED  
IMPORTANT 
MEMBERS 
BETA-LACTAMS Peptidoglycan 
synthesis 
Penicillin Binding 
proteins 
Penicillins (Penicillin G & V, 
ampicillin, amoxicillin, 
carbenacillin)    
Cephalosporins (cefotaxime, 
ceftazidime, cefoperazone)    
Carbapenems (ertapenem, 
faropenem, impenem) 
GLYCOPEPTIDES Peptidoglycan 
synthesis 
PG amino acid sidechains ramoplanin, vancomycin, 
teicoplanin 
AMINOGLYCOSIDES Protein synthesis 30S ribosomal subunit Amikacin, gentamicin, 
streptomycin tobramycin 
TETRACYCLINES Protein synthesis 30S ribosomal subunit Tigecycline 
MACROLIDES Protein synthesis 50S ribosomal subunit clarithromycin, erythromycin, 
midecamycin, spiramycin 
STREPTOGRAMINS Protein synthesis 50S ribosomal subunit Quinupristin/dalfopristin, 
pristinamycin 
RIFAMYCINS RNA synthesis RNA polymerase Rifabutin, rifampin, rifaximin 
QUINOLONES DNA synthesis Topoisomerase II & IV Cinoxacin, ciprofloxacin, 
enoxacin, moxifloxacin, 
pipemidic acid 
POLYMYXINS Cell Membrane Lipopolysaccharides Polymyxin B & E 
Table 1. Antibiotics classified as critical or highly important by the WHO. Whilst many 
target similar metabolic pathways, the is significant diversity in the targeted proteins or 
substrates (Collignon et al., 2009) 
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 Due to the reliance decades (Brown and on these established families of antibiotics, research 
into novel targets has been lacking in recent Wright, 2016). Whilst novel approaches in 
recent years have been developed, such as genomic exploitation (looking at highly conserved 
genetic sequences for potential targets) and the development of the iChip device (able to 
grow and extract products from previously unculturable bacterial species), they have not 
been able to repeat the successes of the Golden Era (Nichols et al., 2010). Payne et al. (2007) 
suspect that this is due to the withdrawal of funding towards novel compounds, with larger 
pharmaceutical companies preferring to develop existing compounds with a higher chance 
of licensing success than researching untested compounds. 
As mentioned earlier, antibiotics target particular areas of metabolic pathways. Improving 
the understanding of these pathways would potentially open up new areas of antibiotic 
development. One essential pathway which is universal to bacterial species is the synthesis 
and modification of peptidoglycan. 
1.3. Peptidoglycan synthesis 
Some groups of antimicrobials have targets involved in the peptidoglycan synthesis 
pathways. This is primarily due to the fact that this process is essential to the growth and 
survival of bacterial cells and, in theory, cannot be dramatically modified easily. 
Peptidoglycan synthesis is carried out in both Gram-positive and Gram-negative bacteria, but 
results in different variations of peptidoglycan (Brown et al., 2015). Gram-positive bacteria 
produce multiple layers of peptidoglycan, which form their cell wall, whilst Gram-negative 
bacteria only have a single layer of peptidoglycan (Popham and Young, 2003). 
The structure of peptidoglycan is formed with crosslinked chains of GlcNAc-MurNAc 
repeating disaccharide units. Much of the formation of peptidoglycan is facilitated by 
glycosyltransferase and transpeptidase enzymes (Figure 1), which catalyse the formation of 
the glycan chains and the production of interpeptide bridges respectively (Lovering, Gretes 
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and Strynadka, 2008). This synthesis occurs in the Gram negative periplasmic space, located 
between the inner and outer membranes (Typas et al. 2011). Glycosyltransferases and 
transpeptidases are found anchored to the inner membrane (all late-stage peptidoglycan 
synthases contain transmembrane anchors), where they can encounter their respective 
substrates.  For glycosyltransferases, Lipid II, which is anchored to the inner membrane via a 
phosphate-undecaprenol molecule; for transpeptidases, the amino acid sidechains 
presented on the nascent chain (Egan and Vollmer, 2012). Glycosyltransferases facilitate the 
production of a nascent chain, also called immature peptidoglycan. Transpeptidases (in 
peptidoglycan synthesis) facilitate the formation of crosslinkages between strands of 
peptidoglycan. Enzymes with a transpeptidase domain are labelled penicillin binding 
proteins (PBPs), due to their ability to covalently bind penicillins (Vollmer and Bertsche, 
Figure 1. Peptidoglycan structure and Synthesis. Lipid II (a disaccharide-pentapeptide 
monomer with a bactoprenol-pyrophosphate anchor) is transported to the periplasm 
where it binds to a glycosyltransferase (GTase). The GTase utilises Lipid II to form a 
nascent chain (immature peptidoglycan). Sidechains branching from the MurNAc 
blocks of the nascent chain are used to form the crosslinks to other chains, utilising 
transpeptidases (TPase). Moenomcyins inhibit the GTases, Beta-lactams inhibit the 
Tpases. 
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2008). Glycosyltransferases and transpeptidases can be found in monofunctional forms, or 
bound together, which produces a bifunctional enzyme (Lovering, Gretes and Strynadka, 
2008). One major bifunctional enzyme is PBP1b, which contains both a transglycosylase and 
transpeptidase domain. 
1.4. Glycosyltransferases 
Glycosyltransferases are defined as enzymes that catalyse the formation of glycosidic bonds 
via the transfer of sugar moieties from donor molecules to acceptor molecules (Sinnott, 
1990). There are currently 103 defined subfamilies of glycosyltransferases according to CAZy, 
the carbohydrate enzyme database (Cazy.org, 2018). It should be noted that the 
International Union of Biochemistry and Molecular Biology (IUBMB) has not officially 
designated subfamilies in glycosyltransferases based on intrinsic structural features, or those 
which act on distinctive substrates. These can be broadly divided into two groups based on 
action; inverting and retaining (Sinnott, 1990). Inverting glycosyltransferases have a similar 
action to inverting glycosidases, in which they invert the anomeric configuration, making 
glycosidic bonds between sugar molecules of opposite stereochemistry (e.g. UDP-glucose to 
Figure 2. Demonstration of the differences between inverting and retaining 
glycosyltransferases. The sections highlighted in red represent the sugar donor 
molecules, which the glycosyltransferases utilise in the phosphate removal (in the case 
of peptidoglycan synthesis Note the variation between the reactive oxygen groups of 
the acceptor molecules. Image reproduced from Coutinho et al. (2003). 
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Beta-glucoside). Retaining glycosyltransferases form glycosidic bonds between sugar donors 
and acceptors with the same stereochemistry (figure 2). 
Peptidoglycan-synthesising Glycosyltransferases are expected to have a three-dimensional 
fold around the active site, which enable the production of polymer chains, such as the 
nascent chain produced during peptidoglycan synthesis (Gloster, 2014). To date, 3 
structurally different folds have been identified; GT-A and GT-B, alongside a third fold found 
in peptidoglycan-modifying enzymes tentatively labelled GT-C (Lovering, Gretes and 
Strynadka, 2008). The GT-A fold (characterised with an α/β/α sandwich, resembling a 
Rossmann fold) and the GT-B fold (consisting of 2 Rossmann domains with a linker region) 
are not conserved to glycosyltransferases, having been seen in other enzyme families such 
as sugar epimerases (Campbell et al., 2000; Breton et al., 2005). GT-C folds contain 8-13 
Figure 3. Representations of ecoPBP1b, as characterised by Sung et al. (2009). A; 
Cartoon representation of the 3D structure, with the 4 major domains (TP: 
transpeptidase, TG: transglycosylase, TM: transmembrane, UB2H) highlighted, as well 
as the position in the cell. B; 2D structure showing α helices and β sheets, and their 
relevant domains. 
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transmembrane helices, and a dependency for lipid-based phosphate-activated donor sugar 
substrates (Albesa-Jove et al., 2013). Glycosyltransferases identified with a GT-C fold to date 
have all been inverting enzymes (Lairson et al., 2008). Glycosyltransferases can be 
monofunctional, where they have a singular transglycosidic function, or bifunctional (with 
additional domains containing other active sites) (Wang et al., 2001). One major GT-A 
bifunctional glycosyltransferase is ecoPBP1b which, as mentioned previously, also contains 
a transpeptidase domain, allowing two concurrent processes required in peptidoglycan 
synthesis (formation of nascent chains and crosslinkage of such chains) (Sung et al., 2009).  
1.5. Transpeptidases 
Transpeptidases are involved in late stage peptidoglycan synthesis. They catalyse the peptide 
bond formation between the D-ala (4) residue and Lys (3) residue located on protruding stem 
peptides of nascent and mature peptidoglycan, which crosslink between the peptidoglycan 
chains (figure 4). This reaction results in the removal of the D-ala molecule from the end of 
a protruding MurNac stem peptide (Lupoli et al., 2011). They are membrane bound and are 
often closely linked with glycosyltransferases, working on the product of glycosyltransferases 
(the aforementioned nascent chain) (Egan and Vollmer, 2012). The transpeptidases were 
first discovered shortly after penicillin, as many were characterised during studies 
determining the mechanism of action of penicillin (Vollmer and Bertsche, 2008). As such, 
many are labelled as penicillin binding proteins (PBPs). The transpeptidases are essential for 
the growth and survival of the bacterial cell, and have been an ideal target for antimicrobials 
due to their highly conserved nature across bacterial species. 
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1.6. E. coli PBP1b 
ecoPBP1b is, as mentioned earlier, a bifunctional glycosyltransferase from family 51. It 
consists of 4 overall domains; a transmembrane domain (TM), a glycosyltransferase domain 
(or transglycosylase, TG), a transpeptidase domain (TP) and a UB2H domain (see Figure 3). 
The TM domain ensures that the overall protein is anchored to the cellular membrane as 
well as containing a hydrophobic region suspected to enable binding of substrates to the TG 
domain. The TG domain produces a nascent chain from Lipid II subunits suitable for 
peptidoglycan synthesis, which is then fed into the TP domain for crosslinking with either 
mature peptidoglycan or other nascent chains (figure 5). The UB2H domain function hasn’t 
been fully ascertained, but is believed to interact with binding partners for the TP domain 
(King, Lameignere and Strynadka, 2014). 
Figure 4. Schematic showing an example of an action of transpeptidases. 
Transpeptidases utilise the MurNac amino acid sidechains to form the peptide 
crosslinkage in mature peptidoglycan. In forming the crosslinkages, the terminal D-
Ala is removed. It should be noted that there are other forms of transpeptidase 
action, and this particular action is one carried out by the transpeptidase of this 
study. 
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Due to the bifunctional nature of ecoPBP1b, it is affected by 2 major classes of antibiotics; 
beta-lactams and moenomycins. Beta-lactams bind to the penicillin binding region located 
on the transpeptidase domain, preventing the crosslinkage step of peptidoglycan synthesis. 
Moenomycins mimic the product produced by ecoPBP1b (including a lipid tail, necessary for 
the entry to the active site), irreversibly binding to the TG active site. 
1.7. Notable Previous Studies of ecoPBP1B 
It has been known that ecoPBP1b is involved in peptidoglycan synthesis since the 1970s 
(Nakagawà, Tamaki and Matsuhashi, (1979); Suzuki, Nishimura and Hirota, (1978)). Several 
studies have focussed on the glycosyltransferase domain, and how moenomycin A binds to 
it, in particular Sung et al. (2009). This study characterised ecoPBP1b with moenomycin A 
bound to the TG active site at a resolution of 2.16Å, which produced further insight into the 
functional ability of ecoPBP1b (Figure 3). This study was notable for being one of the first 
studies to characterise the entirety of ecoPBP1b (with all 4 domains).   
Figure 5. Mechanism of action of ecoPBP1b to elongate the nascent chain, utilising lipid II. 
The Glc-Nac 4-OH is deprotonated by the TG domain, which directly attacks the C1 of the 
nascent chain-linked MurNac structure.  
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An issue with the Sung et al. (2009) characterisation was the potential ambiguity of structural 
residues, such as the exact locations of residues in the region of H240-T267 (highlighted by 
King et al. (2016)) within the electron density map produced by this study. This allowed for 
some degree of interpretation to be involved. In addition, it appears that they characterised 
ecoPBP1b with no stabilising beta-lactam such as ampicillin. Whilst there are imperfections 
with this study, Sung et al. (2009) did provide a basis for further expression and 
characterisation of ecoPBP1b, much of which was utilised in this research project.  
A major problem with characterising the exact mode of action that is carried out by 
ecoPBP1b (and other monofunctional glycosyltransferases) is the current lack of Lipid II in 
enough quantity to test (Cheng et al., 2008). There have been some studies attempting to 
produce synthetic of variations of Lipid II (such as a truncated version which is expected to 
contain the substrate activity). However, the quantities produced are currently insufficient 
for extensive studies. 
Another key study was carried out by King et al. (2016), in which they carried out studies 
comparable to this project: looking at the binding of moenomycin to the TG domain, as well 
as binding a number of beta-lactam-based substrates such as ampicillin, cephalexin and 
CENTA. CENTA is a chromogenic cephalosporin which can be used to crudely identify the 
presence of various beta-lactamases (Bebrone et al., 2001). They found that the 
conformation of the active site largely remains unchanged when substrates are bound, with 
the exception of the side chain at S510 (the catalytic residue), which was believed to position 
the oxygen of the beta-lactam structure into the oxyanion hole.  
This implies that the majority of changes made to the beta-lactam structure for 
antimicrobials is not for altering or changing binding affinity, but for improving the 
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pharmacological effects (bioavailability, broadness of action, avoiding resistance, for 
example). 
In order to respond to the antimicrobial crisis, we need to develop novel compounds. 
Development of such compounds requires an improved understanding of the interactions 
that occur between current (and novel) compounds and their targeted active site. If these 
interactions can be elucidated, design of these compounds can be aimed towards overall 
improvements (decreasing likelihood of resistance mechanisms developing) or specific 
qualities, such as beta-lactamase resistance or better pharmacological properties. 
1.8. Aims and Objectives 
It was proposed that ecoPBP1B can be used to elucidate the binding of novel antimicrobial 
compounds based in 2 antibiotic classes; beta-lactams and moenomycins. Previous studies 
have looked at using the singular domains for study, as opposed to using the whole model. 
Using novel moenomycin analogues produced at the University of Lincoln, in conjunction 
with a range of clinically approved beta-lactams, structures of ecoPBP1B in complex with 
these compounds were produced.  
The aims were twofold; Firstly, to examine the binding of the MoeA analogues, looking at 
whether the alterations to the MoeA structure have affected binding affinity. Secondly, to 
examine the conformational changes caused by the binding of beta-lactams to the penicillin 
binding site, which may show how the different side chains of such compounds affect the TP 
domain. This was achieved by using E. coli to produce quantities of ecoPBP1b to be purified 
and crystallised in conjunction with the aforementioned ligands.  
 
 
12 
 
Aims:  
Primary Aim: To define the interactions between novel moenomycin A analogues AI167-p           
                         and AI168-p in the glycosyltransferase domain of ecoPBP1b. 
Secondary Aim: To model the effect that differing beta-lactam based compound cause on  
                             the transpeptidase domain of ecoPBP1b. 
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2. Moenomycin 
2.1. Introduction 
Moenomycin A (MoeA) is an important compound in the development of effective counters 
to antimicrobial resistance. MoeA, a member of the moenomycins family of antimicrobials, 
is a naturally occurring phosphoglycolipid able to interfere with the synthesis of 
peptidoglycan (Van Heijenoort et al., 1987). The structure of MoeA was identified by Welzel 
et al. (1981, 1983), but has yet to see wide clinical applications. Its primary use to date has 
been as a growth promoter in animal feeds, under the names flavomycin and bambermycin 
(Halliday et al., 2006). What makes Moenomycin A notable is that whilst it has been used for 
decades as a growth promoter, environmental resistance has been shown to be negligible in 
E. faecalis and S. aureus, both of which are species known to develop rapid resistance 
(Butaye, Devriese and Haesebrouck, 2001, White et al., 2003). 
2.1.1. Mode of Action of Moenomycin A 
Moenomycin A targets transglycosylase enzymes involved in the formation of the nascent 
chain required for peptidoglycan synthesis, notably those in family 51. This area of 
peptidoglycan synthesis has been largely overlooked until recently in favour of the 
transpeptidase classes of enzymes, targeted by Beta-lactams (Halliday et al., 2006). This 
could be primarily due to the membrane-bound nature of transglycosylases, which makes 
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them significantly harder to study than the transpeptidase class of enzymes (Lovering, Gretes 
and Strynadka, 2008). 
Moenomycin A has been shown to bind reversibly to E. coli PBP1B and 1C, as well as the 
homologous transglycosylases found in Staphylococcus aureus (Di Guilmi et al. 2003, 2003). 
Initially hypothesised to compete for the active site against the naturally occurring substrate 
Lipid II, it is now known that it competes with the growing nascent chain produced by the TG 
domain, preventing the addition of further Lipid II molecules. It does this by mimicking the 
Figure 6. The structure of Moenomycin A, a known potent inhibitor for bacterial 
transglycosylases. The region highlighted in blue is the minimal inhibitory pharmacophore, 
which is often used as a scaffold for the design of new potential inhibitors. The sugar units C, 
E & F are the minimal units required for antibacterial activity. E & F still inhibit TG function, 
but lack antibacterial activity. Units A, B and D have no impact on antibacterial activity 
(reproduced from Galley, O’Reilly and Roper (2014). 
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disaccharide–pyrophosphate–prenol linkage naturally formed between the transglycosylase 
domain and Lipid II (Zuegg et al., 2015). 
2.1.2. Structural Characteristics of Moenomycin A 
Its ability to inhibit transglycosylases is predominantly down to 2 major characteristics; the 
binding of the F-ring and phosphoglycerate sections to 6 highly conserved residues (E83, 
S116, Q121, K124, R132, K137, as identified in Aquifex aeolicus PBP1A) located in the 
transglycosylase active site (Yuan et al., 2008), and the lipid tail, which allows access to the 
TG active side buried within the inner membrane of the cell. In addition, it has been noted 
that the lipid tail interacts with the transmembrane domain, demonstrated by Cheng et al. 
Figure 7. 3D representation of Moenomycin A bound to the active site of 3D3H, a PBP1a 
found in A. aeolicus. Highlighted in green are the 6 residues that Yuan et al. (2008) 
identified as binding to the F ring and phosphoglycerate sections. These identified residues 
were used in conjunction with subsequent PBP1b models to identify relevant catalytic 
residues.  
16 
 
(2008) who removed the transmembrane domain of a PBP1B, which then showed a five-fold 
decrease in the binding affinity of MoeA. This TM-MoeA interaction is most likely due to a 
‘hydrophobic patch’ on the TM domain, which is hypothesised by Yuan et al. (2007) to act as 
a recognition site for binding substrates such as Lipid II.  
2.1.3. Effectiveness of Treatments 
Whilst MoeA has been shown to have good activity against Gram positive bacterial species, 
it has a reduced impact when tested on Gram negatives. Moenomycin A is believed to enter 
the cell via passive diffusion, as opposed to active transport (transport proteins or influx 
pumps), based on its increased effectiveness on cells with increased cell wall permeability 
(Ostash and Walker, 2010). Due to the nature of the Gram negative outer membrane, the 
A 
B 
Figure 8. Demonstration of the inability of MoeA to pass through outer membranes. 
A; MoeA unable to pass through the phospholipid bilayer, due to the carboxylate 
and phosphate groups (highlighted in blue). B; MoeA with positively charged cell-
penetrating peptide and linker attached (circled in red), able to pass through the 
outer membrane and access the periplasm. 
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presence of negatively charged carboxylate and phosphate groups reduces moenomycin’s 
ability to enter the negatively charged environment of the cell (Halliday et al., 2006). This, 
combined with a reduced bioavailability in the bloodstream caused by the hydrophobic lipid 
tail (necessary for the binding of MoeA to both the TM and TG domains) is one of the major 
factors why Moenomycin A, and by the same distinction the other moenomycins, has not 
been used in a clinical setting. Unfortunately, these issues cannot be resolved purely by 
truncating the lipid tail, as doing so will most likely prevent any analogues from accessing the 
TG active site. The addition of cell-penetrating peptides may be able to overcome such 
difficulties (figure 8). Many such peptides are comprised of positively charged residues, in 
order to attract compounds to the negatively charged outer membranes of bacterial cells 
and overcome the effects of carboxyl and phosphate groups. 
2.1.4. Recent Developments 
Moenomycin A has had somewhat of a resurgence in recent years, due to the recent current 
focus on antimicrobials resistance and the need to develop novel compounds. A large portion 
of the research has been to alter both the bioavailability, and to broaden its treatments 
applications (predominantly, targeting Gram Negatives). A notable fact to emerge in the last 
25 years regarding MoeA is that fragments of MoeA still demonstrate antimicrobial effects. 
This produced a study by Sofia et al. in 1999, in which the pharmacophore (the sections of a 
molecule which have pharmacological effects) was identified by comparing 1300 analogues 
of MoeA at critical binding points to transglycosylases. This pharmacophore was compiled 
by Galley, O’Reilly and Roper (2014).  
2.1.5. Preliminary Findings 
Previous research carried out as part of the University of Lincoln Drug Design and Delivery 
Group has been looking into alterations to moenomycin A, aiming to improve the 
bioavailability of the compound, in addition to improving its treatment efficacy against 
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clinically important Gram Negative pathogenic bacterial species (Acinetobacter baumanii, 
Klebsiella pneumoniae, Pseudomonas aeruginosa). MIC testing of altered compounds such 
as AI167 and AI168 showed marked decreases in the quantities required to inhibit growth 
(table 2). This has provided a basis for further study into the mode of action of peptide-bound 
MoeA compounds.  
 
 
 
2.1.6. Research Aims 
This chapter of research primarily covers one facet of the rational design approach; testing 
the binding efficacy of Moenomycin A analogues to a predetermined target: E. coli PBP1B. 
These compounds have had cell-penetrating peptide additions made to the A- ring located 
opposite the lipid tail (A subunit), as this has been identified in previous studies not to 
interfere with the binding of MoeA to transglycosylase functions.  
Compound P. aeruginosa ATCC 27853 K. pneumoniae ATCC 
700603 
A. baumannii ATCC 19606 
 
MIC (µg/ml) MIC (µg/ml) MIC (µg/ml) 
Moenomycin A 256 64 4 
AI167-p 16 4 64 
 
16 8 64 
 
16 4 64 
AI168-p 32 32 128 
 
16 32 128 
 
16 32 128 
 
MBC (µg/ml) MBC (µg/ml) MBC (µg/ml) 
AI167-p 256 256 128 
 
256 256 256 
 
256 256 128 
AI168-p 256 64 128 
 
256 128 256 
 
256 128 256 
    
Table 2. Antimicrobial efficacy of the two moenomycin A analogues AI167-p and AI168-p 
as compared to the original compound. As can be seen, the two analogues perform 
better against P. aeruginosa and K. pneumoniae. 
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The bifunctional glycosyltransferase E. coli penicillin binding protein 1b (also known as 
ecoPBP1b) was chosen to model the MoeA analogues. Its bifunctional nature was utilised in 
a later chapter of this project as well, looking at another class of antimicrobial compounds.  
Specifically, this chapter looked  at two major question: What is the nature of the active site 
binding of the new MoeA-peptide conjugates; and have the increase in MICs observed 
caused by new interactions with the transglycosylase binding? 
In order to answer these questions, structural biological techniques will be utilised to 
determine any changes in the binding to the TG domain. 
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2.2. Methods 
2.2.1. General Methods 
2.2.1.1. Plasmid DNA Miniprep 
Bacterial plasmids containing the entire ecoPBP1B gene (TM, TP, UB2H, TG) were purified 
from XL1-Blue supercompetent E. coli cells with the use of the QIAprep Spin miniprep kit 
(Qiagen). All the reagents and buffers (with the exception of the LB broth) came as part of 
the aforementioned kit. Single colonies from an XL1-Blue transformation were selected and 
grown in 5ml LB broth (Melford) cultures with ampicillin (50µg/ml) overnight. These cultures 
were pelleted at 8000rpm for 3 minutes in 2ml microcentrifuge tubes, and the protocol 
provided by Qiagen was followed to purify the plasmid samples (QIAprep® Miniprep 
Handbook, 2017). Purified plasmid samples were then stored at -20⁰C until use. 
2.2.1.2. Calcium Competent cell production 
Competent BL21 (DE3) pLysS E. coli cells were produced for plasmid transformation and 
ecoPBP1b expression. 
Colonies of BL21 cells were streakplated on LB agar from glycerol stocks, and incubated at 
37⁰C overnight. Single colonies from these plates were used to inoculate 5ml LB broth 
cultures, and left to grow overnight in an orbital shaker at 37⁰C, 180rpm. 0.25ml of the 5ml 
broth culture was used to inoculate a 50ml LB broth culture, and grown at 37⁰C to an OD600nm 
of 0.2. Once the OD600nm was achieved, the cultures were cooled on ice.  
Cultures were centrifuged at 3000g for 10 minutes, and the supernatant subsequently 
removed. Pelleted cells were resuspended in 5ml of ice-cold MgCL2 (0.1M), left to stand for 
5 minutes, and centrifuged at 3000g for 5 minutes. Once the supernatant had been removed, 
the pelleted cells were resuspended in 2.5ml of ice-cold CaCl2 (0.1M), and left to stand for 5 
minutes. After centrifuging at 3000g for 5 minutes, the supernatant was removed and the 
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pellet resuspended in 0.5ml of ice-cold CaCl2 (0.1M). The resuspension was kept on ice for a 
minimum of 90 minutes, before adding glycerol (to a final percentage of 15), and being 
aliquoted out in 100µl batches. The aliquots were flash frozen in liquid nitrogen and stored 
at -80⁰C until use. 
2.2.2. Expression and Characterisation of ecoPBP1b 
2.2.2.1. Transformation of Expression Cells 
100µl of E. coli BL21 (DE3) pLysS cells were defrosted on ice after storage at -80⁰C, and 3µl 
of plasmid DNA (containing pET15b plasmids with the ecoPBP1b insert) added. The cells were 
incubated on ice for 30 minutes after DNA addition. Once incubated, the cells were heat 
shocked at 42⁰C for 45 seconds, before being cooled on ice immediately afterwards for 1-2 
minutes. 250µl of SOC media (2% w/v tryptone, 0.5% w/v Yeast extract, 10mM NaCl, 2.5mM 
KCl, 20mM glucose) was added, before the transformed cells were incubated at 37⁰C for 60 
minutes. After incubation, 100µl of the cell culture was spreadplated on LB agar with added 
ampicillin (50µg/ml), and grown overnight at 37⁰C. Chloramphenicol was not used to retain 
the PLysS gene during this research. 
2.2.2.2. Expression of ecoPBP1b 
4-7 colonies (depending on the quality of the previous transformation) of transformed  E. 
coli BL21 (DE3) pLysS cells were removed and used to inoculate 5ml LB broth cultures. This 
was repeated until 7 independent cultures had been prepared. These were incubated in an 
orbital shaker overnight at 37⁰C and 180rpm. 6 cultures of 500ml autoclaved LB broth with 
added ampicillin (to a final concentration of 50µg/ml) were preheated to 37⁰C. The 500ml 
cultures were inoculated with 5ml of the overnight cultures, and grown to an OD600nm of 0.6 
at 37⁰C and 180rpm. Once the OD of 0.6 was achieved, Isopropyl β-D-1-
thianogalactopyranoside (IPTG, Melford) was added to each 500ml culture (to a final 
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concentration of 1mM) to induce expression. The cultures were left to express at 30⁰C in the 
orbital shaker at 180rpm for 5 hours. 
After expression, the 500ml cultures were centrifuged in a Beckman-Coulter Avanti 
centrifuge (using 500ml Beckman tubes in a JLA-10.500 rotor) at 15000g for 20 minutes, at a 
temperature of 4⁰C. the supernatant was discarded, and the pellet was resuspended in 30ml 
of resuspension buffer (20mM TRIS pH 8.0, 150mM NaCl), and stored at -20⁰C until use. 
2.2.2.3. Cell lysis and Preparation of cell samples for purification 
Resuspended cell samples were defrosted and sonicated for 6 minutes (5 seconds on, 5 
seconds off, for a total of 12 minutes per sample) at 30mA. Sonication was carried out using 
a Fisher Scientific FB705 sonic dismembrator with a 3/16 inch probe. After sonication, the 
cell extracts were decanted into 50ml Beckman centrifuge tubes and pelleted using the 
Beckman-Coulter Avanti centrifuge (using the JA-25.50 rotor) at 30000g for 20 minutes, at a 
temperature of 4⁰C.  
The supernatant was decanted off and stored at 4⁰C as the soluble fraction. The insoluble 
pellet was resuspended with 10ml of buffer (20mM Tris pH 8.0, 150mM NaCl, 20mM n-
Dodecyl-β-D-Maltopyranoside (DDM)). This suspension was centrifuged using the same 
centrifuging conditions as the step before, to produce another supernatant and pellet. The 
supernatant was removed and stored at 4⁰C as the DDM-containing fraction . The storage 
times for the soluble and DDM-containing fractions did not exceed 3 days, in order to limit 
ecoPBP1b degradation. 
2.2.2.4. ecoPBP1b Purification 
The DDM-containing fraction was loaded onto a 5ml HisTrap nickel column (GE Healthcare) 
at 1ml/minute for 3 hours by an AKTA Prime Plus (GE Healthcare), and was recirculated 
throughout. Whilst being loaded, the DDM-containing fraction was kept on ice.  
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Once loaded, the column was washed with 8 column volumes (40ml) of Buffer A (20mM Tris 
pH 8.0, 150mM NaCl, 1mM DDM), and the protein eluted with a 20 column volume (100ml) 
gradient of Buffer B (20mM Tris pH 8.0, 150mM NaCl, 1mM DMM, 1M imidazole). This 
gradient was a gradual increase of Buffer B concentration from 100%/0% of Buffer A/Buffer 
B respectively at the start through to 0%/100% of Buffer A/Buffer B at the 100ml mark. 10ml 
fractions were collected during the wash phase, and 5ml fractions were collected during the 
elution phase. Once purified, the fractions were collected and stored at 4⁰C until used. 
2.2.2.5. SDS-PAGE confirmation 
In order to determine the fractions containing purified ecoPBP1Bb, samples of the fractions 
were run on a 12% SDS-PAGE gel. The samples were prepared as follows; 
20µl of sample and 20µl of 2x SDS loading buffer (60mM Tris pH 6.8, 10% w/v of glycerol, 2% 
w/v SDS, 0.05% bromophenol blue, 5% w/v of β-mercaptoethanol) were added together. 
Samples were taken from the soluble fraction, DDM-containing fraction (prior to loading), 
flow-through and wash steps, as well as from the fractions collected after elution. Only 4µl 
of the DDM-containing and soluble fractions were used, and they were made up to 20µl with 
18MΩ autoclaved water before 2x SDS loading buffer was added. Once mixed, the samples 
were heated to 95⁰C for 3-5 minutes before being loaded onto the 12% SDS-PAGE gel. The 
gel was composed of a 12% resolving gel (3ml resolving gel buffer (1.5M Tris pH 8.8, 0.4% 
SDS v/v), 4.8ml 30% w/w acrylamide/bis-acrylamide solution (Sigma-Aldrich, product code 
A3574), made up to 12ml with 18MΩ autoclaved water, and polymerised with 100µl  of 10% 
ammonium persulfate (APS) and 16µl N,N,N’,N’-Tetramethylethane-1,2-diamine (TEMED)), 
and a 4% stacking gel (1.3ml stacking gel buffer (0.5M Tris pH 6.8, 0.4% SDS v/v), 0.7ml 30% 
acrylamide/bis-acrylamide, made up to 5ml with 18MΩ autoclaved water, polymerised with 
50µl APS and 16µl TEMED). The gel was run at 60mA for 80 minutes, submerged in 1x SDS 
running buffer (25mM Tris, 192mM glycine, 0.1% SDS). A Precision Plus Protein Standard 
(Biorad) was also run alongside the fraction samples. 
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Once run, the gels were submerged in Coomassie Brilliant Blue stain (BioRad) (2g Coomassie 
Brilliant Blue Stain, 100ml acetic acid, 250ml propan-2-ol, 650ml 18mΩ autoclaved water), 
and microwaved for 30 seconds before being left to stand on a rotary table for 5 minutes. 
Once stained, the Coomassie was removed, and the gel underwent 3 changes of 1x destain 
(5% v/v propan-2-ol, 7% v/v acetic acid, 88% 18MΩ water).  
Each change consisted of the gel being submerged in 1x destain, and left to stand for 15 
minutes, before the destain was poured off. Gels were stored in 1x destain until imaged as 
required. 
2.2.2.6. Concentration and Thrombin Cleavage 
Fractions containing purified ecoPBP1b were concentrated down to a final volume of 5ml, 
using a Vivaspin 20 column (selective to 50kDa) (Sartorius). This was carried out using an 
Eppendorf 5810-R, with an S-4-104 square bucket rotor. RPM and time varied, from 1000-
4000 rpm and 1-5 minutes respectively, depending on the volume required and rate of 
concentration. The 5ml protein solution was decanted into a 15ml falcon tube in preparation 
for thrombin cleavage. 3µl of Biotinylated thrombin (approximately 3 units, at 1unit/µl), 
alongside 200µl of 10x thrombin buffer (Novagen) were added, and incubated at room 
temperature for 16 hours. 
Once cleaved, the 5ml of protein was manually loaded onto a 1ml HisTrap FF column (GE 
healthcare) to remove the cleaved His-tags, and the flowthrough collected in 1ml fractions. 
The column was then washed with 3ml of Buffer A, and eluted with 5ml of Buffer B, all 
collected in 1ml fractions. Using the previous method of SDS-PAGE, samples of the fractions 
were run on a 12% SDS-PAGE gel, in order to confirm the completion of the thrombin 
cleavage. 
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2.2.2.7. Buffer Exchange 
Once the fractions containing purified cleaved ecoPBP1b were identified, they were collated 
together and concentrated using a Vivaspin 2 column (selective to 10kDa) to a volume of 
1ml. 1ml of 4.5mM N-decyl-β-D-maltopyranoside (in 20mM Tris pH 8.0, 150mM NaCl) was 
added, the combination was subsequently concentrated to 1ml.  
This was repeated (with a final total of 2ml 4.5mM N-decyl-β-D-maltopyranoside being 
used), before the same process was carried out with 0.28mM N,N-Dimethyldodecylamine N-
oxide (LDAO) (in 20mM Tris pH 8.0, 150mM NaCl), with a final volume of 2ml of LDAO in 
resuspension buffer being used. These detergents and concentrations were identified as 
being able to maintain the stability of ecoPBP1b in aqueous solutions for crystallisation 
purposes in previous works of research (Sung et al., 2009).  
2.2.2.8. Crystallisation 
After buffer exchange had been carried out, the protein solution was concentrated to 
10mg/ml, quantified using a Nanodrop 2000 (Thermo Scientific), using the flowthrough from 
the concentrator to blank. The Nanodrop 2000 was set to measure absorbance at 
260/280nm, using the extinction coefficient of ecoPBP1b (104.865 M-1 cm-1) as well as the 
molecular weight (83.16kDa). 
Once concentrated to 10mg/ml, ampicillin (50mg/ml, in a ratio of 1µl to 20µl of concentrated 
protein sample) and moenomycin conjugates (50mg/ml, in a ratio of 1µl to 20µl of 
concentrated protein sample) were added. 24 well plates with 1ml well volumes (Molecular 
Solutions) were used to set up the conditions for crystal growth. The crystallisation solution 
consisted of 1.22M sodium formate, as found by previous studies. Siliconised cover slips 
were polished using a silk cloth to remove dust and surface contaminants. 1µl of 
protein/ligand mixture was added to a siliconized cover slip, and 1µl of mother liquor (1.22M 
sodium formate) was mixed in. the slips were sealed into the tray wells using vacuum grease 
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(Dow Corning), and incubated at 16⁰C for up to 2 weeks. Trays were checked after 5 days for 
signs of crystal growth, and trays with no growth at 2 weeks were removed. Trays with crystal 
growth were monitored until crystals were of a sufficient size. 
Once fully grown, crystals were collected with  loops and stored in a cryo-preservative 
solution (3M sodium formate) in liquid nitrogen. Chosen crystals were sent for X-ray 
diffraction data collection at the Diamond Light Source Synchrotron (Oxford). 
2.2.2.9. Inducing Nucleation 
It was noted in early trials that the numbers of suitably sized crystals were lower than 
expected. It was hypothesised that there may have been issues with nucleation occurring 
with ecoPBP1b, as a contaminated well containing a silk hair had grown crystals along the 
length of the hair (figure 9). 
 
 
 
 
 
 
 
 
In order to improve the number of suitable crystals grown, a preliminary trial applying a 
variety of hypothesised nucleation techniques was formalised, partially based off the works 
of Georgieva et al. (2007). A 24 well plate was set up with 1.22M sodium formate, and the 
hanging drop method used as previously described. 4 techniques were utilised; 6 wells were 
Figure 9. ecoPBP1b/AI168 crystals grown on a strand of silk in 1.22M sodium formate. 
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seeded using fragments of previously grown ecoPBP1b crystals, using a hypodermic needle 
to transfer the fragments from one drop to the next.  
Another 6 wells had a single horse hair (chosen for the keratin structure) dragged through 
the protein/motherliquer drops. A further 6 wells had small fragments of horse hair 
deposited in the protein/motherliquer drops. The last 6 wells of the 24 well plate had 
fragments of silk deposited, from the same source of the contaminant hair of the previous 
crystal tray. Once the wells were sealed, the tray was left to incubate as previously described. 
2.2.2.10. Diffraction Data Processing 
X-ray data were processed automatically at the Diamond Synchrotron using xia 2. All 
Programs used to refine and produce a data set were found in the CCP4i Program suite. Xray 
Diffraction Data was used in conjunction with native ecoPBP1b dataset 3VMA and MolRep 
to solve the structure. An electron density map was calculated using RefMac, and automatic 
structural refinement was carried out using alternate cycles of RefMac and WinCoot. This 
model was then exported into PyMol for analysis and figure production. Distances between 
relevant residues and structures were measured in WinCoot. 
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2.3. Results 
2.3.1. Protein Expression 
The UV chromatograph data collected from the AKTA Prime Plus shows an increase in 
absorbance during the elution of the Histrap column with imidazole, as indicated by the 
chromatograph in figure 10. The SDS-PAGE gels (once stained) show good expression of 
ecoPBP1b (Figure 11), backing up the UV data. What is noted that the addition of DDM used 
in the resuspension of the initial insoluble pellet allows ecoPBP1b to be solubilised in 
resuspension buffer, as shown by the increase in the gel at 83kDa in the DDM-containing 
fraction (and lack thereof in the soluble fraction). The binding on the column is demonstrated 
by the visible decrease shown between the DDM-containing fraction (collected prior to 
column loading) and the flowthrough collected after repeated cycles. Later fractions 
collected from the addition of imidazole across a gradient shows large quantities of 
ecoPBP1b being expressed and successfully purified.  
2.3.2. Thrombin Cleavage 
Figure 12 shows good success in the thrombin cleavage. Large amounts of ecoPBP1b (shown 
at the 83kDa mark) are no longer binding to a nickel ion column, indicating that the histags 
have been successfully removed by the thrombin enzyme.
  
2
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Figure 10. UV chromatograph trace showing the UV absorbance during the initial purification step using the AKTA Prime Plus. The bottom axis 
also shows the volume and number of fractions collected. The green line indicated the concentration of Buffer B (elution buffer) to Buffer A, 
which started to increase from 40ml onwards. Fraction 1 was used to represent the wash phase. Fractions 8 onwards were used for subsequent 
testing, due to the location of the peak. It should be noted that the peak doesn’t directly correspond to the location and amount of the target 
protein, due to the weak binding of other proteins, and due to the UV absorbance of DDM. 
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Figure 11. SDS-PAGE stained gel. Well 1; Precision Plus Dual Marker Protein Standard, 
Well 2; Soluble fraction, Well 3; DDM-containing Fraction (resuspended with 20mM 
DDM), Well 4; Flowthrough, Well 5; 1st Wash fraction collected, Wells 6-10; Fractions 
collected during elution, from the peak indicated on the UV spectra graph onwards. 
ecoPBP1b has a molecular weight of 83.19kDa, as indicated by the dotted line. 
Figure 12. SDS-PAGE gel post thrombin cleavage. Gel 1: Well 1; Protein marker ladder, 
Wells 2-6; Flowthrough fractions of thrombin cleaved solution through nickel column, 
Wells 8-10; Wash fractions. Gel 2: Well 1, 3-6; fractions collected from column elution 
with 1M imidazole. The dotted line indicates the estimated size of ecoPBP1b (83.19kDa) 
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2.3.3. Crystal growth 
Whilst successful in growing crystals, the number of crystals grown in early attempts was 
lower than expected, and many were appearing warped and twinned (Figure 13). It was 
hypothesised that there could have been nucleation issues. 
 
2.3.4. Seeding/nucleation Trials 
Preliminary seeding trials were carried out, as previously described in the methods. The 
seeding method produced large quantities of crystals, at the cost of overcrowding in a 
number of the wells (figure 14). 
Figure 14. ecoPBP1b/AI167p complex crystals produced with the addition of seeding. The 
images are numbered in the other that they were seeded (Image 1 being the first well 
after crystal fragments were collected by the needletip, through to image 6 being the last 
seeded well. Crystals were taken from wells 3-6 for imaging. 
Figure 13. A selection of crystals produced in early ecpPBP1b/AI167p and 168p complex 
attempts. It should be noted that these are the more successful attempts at growing 
such crystals, many early trays had no clear growth. Image 1 shows crystal growth along 
a contaminating thread, which was an early inspiration in the seeding trials. In particular, 
image 3 shows ‘twinning’ of the crystals, which wasn’t observed in later trials. 
1 2 3 
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The wells which had the strand of horsehair dragged through it, whilst showing some crystal 
growth, were not as increased as the seeding techniques, shown in Figure 15.  Of the wells 
that had horse hair fragments in, only 2 showed any crystal growth, and of the crystals grown, 
none were of collectable quality (Figure 16). The wells containing strands of silk showed low 
to no growth during incubation, in contradiction of the initial expectations. 
 
 
Figure 15. Crystals grown with horse hair dragged through the hanging drop. Larger 
crystals were observed in these trials, but the numbers of collectable crystals were not 
profoundly increased as compared to the original trials. 
Figure 16. Images of the attempts to use fragments of horsehair and silk to induce 
nucleation and crystal growth. Image 1 shows precipitation but no growth around the 
hair fragment, images 2 and 3 show slight growth, but none of a suitable size. Image 4 
shows a small amount of growth on the silk strand itself, but 5 and 6 show standard 
growth, irregardless of the presence of the silk strand. 
1 2 3 
1 3 2 
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Due to the increased crystal growth using seeding as a method to induce nucleation, 
subsequent crystal trays set up with ecoPBP1b/moenomycin conjugates also utilised 
seeding. This appeared to increased the output of crystals. 
2.3.5. X-ray Diffraction and Structural Solving 
Due to inherent poor diffraction, the crystals were screened at the Diamond Light Source 
Synchrotron. Those of the highest resolution were collected; 2 crystals grown in the presence 
of ligand AI168-p and one in the presence of ligand AI167-p. Of the 3 data sets, the one 
containing AI167-p had the best resultant structure. ecoPBP1b in complex with AI167p and 
ampicillin has been built, showing the binding of ampicillin (used to stabilise the ecoPBP1b 
structure) and the peptide subunits of MoeA (figure 217). However, the alterations made to 
MoeA cannot be seen. This implies that the alterations made to produce AI167-p and AI168-
p do not alter the binding of these compounds to the transglycosylase domain of ecoPBP1b. 
The other collected structures (both containing AI168-p) showed no obvious differences in 
the binding of MoeA conjugates, and can be found in the appendices. 
 
  
 
Resolution  (Å) 2.72 
Space Group  P: 21, 21, 2 
Unit Cell dimension (Å) 63.410, 298.370, 62.480 
Measured Reflections 21916 
Unique Reflections 20624 
Overall Completeness (%) 99.0837 
Average Fourier Shell Correlation 0.825 
Average Free Fourier Shell 
Correlation 
0.8022 
Rfactor 0.2609 
Rfree 0.3233 
Table 3. Diffraction Data and structural solving data for the ecoPBP1b crystallised in 
the presence of AI167-p and ampicillin. 
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Figure 17. 3D models of ecoPBP1b with AI167p and ampicillin bound. 1; Full ecoPBP1b 
model, with ligands highlighted in blue. The top of the model shows ampicillin bound to 
the transpeptidase domain, and AI167p can be located at the bottom. 2; Close-up of the 
transglycosylase active site, with active residues identified in Sung et al. (2009) as 
involved in substrate binding labelled, and coloured in cream. 3; Overlay of the 
transglycosylase active site of ecoPBP1b (residues in red, AI167-p in blue) and 5HL9 
(residues in light green, MoeA in dark green).  
1 
3 
2 
35  
 
 
 
2.4. Discussion 
2.4.1. 3D Structural Developments 
The results show a structure of ecoPBP1b has been produced with clearly identifiable ligands 
bound. This structure allows for the visual identification of 3 of the 4 domains that ecoPBP1b 
is known to have; the transmembrane domain protruding from the base, the 
transglycosylase domain, as shown with the MoeA-based structure bound, and the 
transpeptidase domain (as indicated with ampicillin bound). The one domain not easily 
identifiable (UB2H) is still most likely there, as it is required for the stability of ecoPBP1b. 
2.4.2. Active Site Interactions 
What was highlighted in the results section was the portion of MoeA analogues that could 
be identified. The section of AI167 that could be characterised is the previously referred-to 
pharmacophore, with the lipid tail and alterations made disordered. The lipid tail is likely to 
be unbound, due to its role in binding to transglycosylases (i.e. acting as an identifier to allow 
access to the TG active site). As such, it may be disordered, unbinding once the MoeA has 
integrated into the TG active site. Being disordered means that it diffracts poorly or not at 
all, which implies that it has not bound at all, whilst the pharmacologically important sections 
(which have remained unaltered) are still able to definitively bind. This was confirmed with 
distances between the active site residues being measured, with 5 major residues (Glu197, 
Gln235, Asn239, Glu254, and Ser322) showing distances between 2.52-2.81Å, with two 
residues (Arg250 and Lys319) showing a binding above 3.20Å, measuring at 3.25Å. Matching 
the findings of previous studies in to the TG domain of PBP1b, we found that the 
moenomycin pharmacophore is stabilised by hydrogen bonding with at least 5 residues 
(those measuring in at <2.90Å), with weaker Van der Waals  interactions from Arg250 and 
Lys319 helping to further facilitate binding whilst allowing a certain degree of movement 
(necessary for the polymerisation nature of the TG domain). 
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What is of more significance is the lack of presence of any peptide alterations made to the A 
ring of MoeA. The changes made to the analogues being tested are primarily based around 
improving bioavailability as well as improving the ability of MoeA to inhibit Gram negative 
species. The primary modification made to MoeA were linked peptides designed to facilitate 
the entry of the MoeA molecule into the periplasm of Gram-negatives. This means that the 
A- ring is a suitable region of MoeA to link changes to, with minimal disruption seen when 
bound to the TG domain. It is positive to notice that any changes made to alter the 
conformation of MoeA in solution (i.e. folding the lipid tail into the centre of the peptide 
structure, preventing binding to unintentional targets) haven’t prevented MoeA from 
binding in its original manner.  
2.4.3. Comparison to previous ecoPBP1b structures 
In addition, a comparison of the ecoPBP1b structure produced as part of this project was 
compared to 5HL9, characterised recently by King  et al. (2016) 5HL9 was produced in 
complex with native moenomycin, as well as ampicillin in the transpeptidase domain. When 
the structures were overlaid in PyMol, clear similarities could be seen. Other than small 
conformational differences (which are to be expected, due to the differences in moenomycin 
analogues), our model corresponds well with this previous data set, including the amino acid 
residues located in and around the active site.  
2.4.4. Crystallisation of ecoPBP1b: Has it been improved? 
An identifiable concern early in the project was the sparse numbers of crystals produced in 
early trials. Having run multiple expressions, the distinct lack of protein crystals was a worry. 
It had been suggested that there could be issues with the nucleation of the crystals. Many 
studies refer to two distinct types of nucleation; homogenous nucleation (where the crystals 
form spontaneously providing the conditions are correct) and heterogenous nucleation 
(where the crystals form on the surface of solids or particles present in the motherliquer). 
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The methods used in early trials relied on homogenous nucleation to occur, using the 
handing drop diffusion method, based on conditions found in previous research projects. In 
one particular trial (as mentioned in the methods), protein crystals grew along a single strand 
of silk. This suggested that whilst the conditions were suitable for crystal growth, there could 
be higher yields if ecoPBP1b complex crystals could be grown using heterogenous nucleation 
methods.  
Building off numerous studies looking into inducing nucleation (most notably Georgieva et 
al., 2007), three different nucleators were used; fragments of previous ecoPBP1b crystals, 
horse hair (using 2 distinct methods), and threads of silk from the same source as the 
contaminant.  
One thing which was particularly surprising about these trials was not the success of seeding; 
seeding using fragments of crystals is a common method of improving the yield of protein 
crystals, as it provides a partially constructed scaffold for the asymmetric protein units to 
build upon. Instead, it was the lack of visible crystal growth in any well containing silk thread. 
This was in direct contrast to the previous attempts to grow crystals, where the silk thread 
was one of only a few wells to produce significant crystal growth (albeit crystals bound to 
the thread themselves which, due to the fragility of the crystals, were not collected for data 
processing). It could potentially be that the thread contaminant was mis-identified, so the 
addition of other types of fabric thread would produce a misleading result. 
The moderate success of the horse hair trials appears to back up the findings of previous 
papers, such as Georgieva et al., (2007), but not to the extent that was expected. The 
hypothesised cause of the nucleation induction in this method are microfragments of keratin 
which are deposited when the hair is dragged through the mother liquor. These 
microfragments are hypothesised to cause protein in solution to deposit on the surface, 
beginning the steps of crystal formation.  Whilst there was crystal growth above the levels 
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seen in prior trials, it was not high enough to warrant further study (certainly, not compared 
to the fragment seeding trials). 
One interesting hypothesis that occurred during these trials is the possibility that 
homogenous nucleation is not as random and spontaneous as expected. The majority of 
methods relying on homogenous crystal formation rely on the protein achieving a so-called 
‘supersaturated’ concentration in mother liquor. There remains the potential that when this 
state is achieved, what is occurring is that minute quantities of the protein are precipitating 
out and aggregating, but not to the extent of triggering mass precipitation. Instead, the 
aggregation could well form a seed from which a crystal could grow. It is not yet known how 
to test this hypothesis, but it is certainly an interesting possibility to consider, as it could 
improve crystal yields in future experiments.  
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3. Beta Lactams  
3.1. Introduction 
The other class of antibiotics studied in the process of this research are the beta-lactams. 
Beta-lactam-based antimicrobials have been used in clinical settings for decades, and their 
mode of action has been known for years, binding to a group of enzymes involved in the 
transpeptidase stage of peptidoglycan synthesis. These proteins are classified as Penicillin-
binding proteins (PBPs), the majority of which were identified following studies into the exact 
activity of penicillin. The majority of research into beta-lactams and their mode of action was 
carried out in the 1970s and 1980s (Spratt, 1975; Strominger et al., 1971; Waxman and 
Strominger, 1983). 
Figure 18. Clinically relevant beta-lactam antibiotics. The majority are bicyclic (with 2 
rings forming the pharmacophore), with others being monocyclic, such as nocardicin and 
the monobactams. Reproduced from Konaklieva (2014). 
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3.1.1. Beta-Lactam Characteristics and Mode of Action 
Beta-lactams are defined by the inclusion of the beta-lactam ring, show in figure X. This beta-
lactam ring, produced by fungi to mimic the D-ala-D-ala termini found on peptidoglycan 
recognised by transpeptidases (Figure 19). Mimicking this structure allows access to the 
active site of such PBPs, where the antibiotic can bind to a catalytic serine residue.  This 
serine opens up the beta-lactam ring, producing an acyl-enzyme complex in the same 
manner that it would normally bind to peptidoglycan (Park and Rafii, 2017). This beta-lactam 
version acyl-enzyme complex disrupts the PBP’s ability to synthesise the peptide bonds 
between nascent chains, as it prevents the second D-ala-D-ala (required for the crosslinking 
process) from binding (Kotra and Mobashery, 1998). Once inhibiting PBPs and being 
incorporated into the peptidoglycan structure, beta-lactams tend to cause cell lysis. This lysis 
is caused by the combination of naturally occurring cellular expansion combined with the 
weakened peptidoglycan, and results in the killing of the bacterial cell. 
3.1.2. Development of Resistance 
Resistance to these compounds comes from 3 predominant mechanisms; production of 
efflux pumps, alterations of PBPs to lower beta-lactam binding affinity, and the production 
of beta-lactamases (Konaklieva, 2014). Efflux pumps have been seen to develop in beta-
lactam resistance, but have limited effects, due to the location of PBPs close to the outside 
Figure 19. Demonstration of the similarities between penicillin and the D-Ala-D-Ala termini. The 
beta-lactam ring has been highlighted in red. This image was reproduced from Zeng and Lin, 
(2013) 
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of bacterial cells (Pan et al., 2016). Altered PBPs additionally present an issue, and can be 
harder to treat, as beta-lactams will be unable to bind to the modified PBPs. There must be 
limits to such modification, as PBPs still require the ability to bind the D-Ala-D-Ala termini to 
function properly, so such modifications tend to revolve around making the active site harder 
to access. Whilst the first two noted (efflux pumps, altered PBPS) have an appreciative effect 
on organism survival, the most important clinically are beta-lactamases. These specifically 
target the beta-lactam ring, inactivating this structure through hydrolysis. The exact number 
of beta-lactamases currently identified varies, with recent estimates of upwards of 2000 
(Bonomo, 2016). 
3.1.3. Beta-Lactamases 
Beta-lactamases can be subdivided using the Ambler system into 4 categories based on 
conserved amino acid motifs; A, B, C, D. These can be broadly split into 2 major groups: 
enzymes which utilise a catalytic serine to form an acyl complex with the beta-lactam ring 
(categories A, C, D), and those which require at least one active-site zinc molecule (category 
B, also known as the Metallo-B-lactamases) (Bush and Jacoby, 2009). 
A significant concern with beta-lactamase-mediated resistance is the extended spectrum 
nature of such enzymes, not only for antibiotic classes but also for bacterial species. Many 
beta-lactamases have effects against multiple beta-lactam classes, due to the conserved 
pharmacophore of many of these antibiotics. In addition, many MDR plasmids (also known 
as MDR cassettes) contain beta-lactamase genes (such as the blaCTX-M-15 gene commonly 
found in resistant E. coli strains) and are able to transfer horizontally (Wilke, Lovering and 
Strynadka, 2005). Horizontal gene transfer enables increased development of resistance (as 
compared to de novo resistance), as well as the possibility for species crossover (Ochman, 
Lawrence and Groisman., (2000); Sieber, Bromley and Dunning Hotopp, (2017)). 
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3.1.4. Overcoming Resistance to Beta-Lactams 
The development of such resistance prompted an ‘arms race’ between scientists and 
bacterial species, producing antimicrobials to avoid beta-lactamase degradation (such as 
methicillin), or developing beta-lactamase inhibitors such as diazabicyclooctanes (Wright, 
1999). Many of these inhibitors are beta-lactam mimics, which are able to target beta-
lactamases directly, but many have little to no direct antimicrobial activity (Coleman, 2011). 
The development of beta-lactams has been a cornerstone of antibiotic research since the 
aforementioned discovery of penicillin. Due to this, many of the new compounds are 
structurally similar to their predecessors. This restriction of diversity in the compounds being 
pushed for clinical usage increases the probability that resistance will develop to these new 
compounds. Being structurally similar means only minor mutations are required for the 
previously mentioned resistance mechanisms (Altered PBPs, transporter proteins, beta 
lactamases).   
One solution to this problem is to develop beta-lactamase inhibitors to be used in 
conjunction with beta-lactam compounds. Such compounds with beta-lactam derived 
structures specifically designed to target these beta-lactamases, preventing the degredation 
of beta-lactams before they bind to PBPs. Due to their similarities to beta-lactam structures, 
it could be hypothesised that such inhibitors could potentially bind to PBPs with inhibitory 
effects. 
3.1.5. Aims and Objectives 
This chapter is based around whether different Beta-lactams bound to the penicillin binding 
region of the TP domain of ecoPBP1b cause differing active site interactions. The 
antimicrobial compounds used were all chosen due to size and structural variations away 
from the identified pharmacophore. In addition, a novel beta-lactamase inhibitor was 
43  
 
 
 
studied, looking to see whether the changes to the beta-lactam core would still allow it to 
bind to the transpeptidase domain.  
Specifically, this chapter looked at one major question; Do differing beta-lactam compounds 
produce major changes in the active site interactions required for binding to the 
transpeptidase domain? 
In order to answer this question, structural biological techniques were used in order to study 
the binding of beta-lactams to the penicillin binding region.  
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3.2.  Alterations to the Methodology 
The methods used in this chapter were almost identical to those used in the moenomycin 
chapter, with one major difference: the usage of different beta-lactams other than ampicillin 
used to bind to ecoPBP1b’s TP domain. Native ecoPBP1b without ampicillin or MoeA was 
found to be unstable, so the addition of compounds from both families was essential. As 
crystals had been produced with AI167 and AI168, these compounds were used 
interchangeably to stabilise the TG domain, whilst different beta-lactam based compounds 
were used as ligands for the TP domain. 
3.2.1. Crystallisation 
Once purified ecoPBP1b had been concentrated to 10mg/ml in LDAO buffer, the 
moenomycin A conjugates were added (10mg/ml stock, in a ratio of 1µl to 20µl of protein 
sample), as well as the chosen beta-lactam (50mg/ml stock, in a ratio of 1µl to 20µl of protein 
sample). The beta-lactams used were; amoxicillin, ampicillin, cefotaxime, cephradine, 
oxacillin and penicillin G. They were selected due to their variances in structure, as well as 
availability (Figure 20). In addition, a novel beta-lactamase inhibitor was trialed, replacing 
the beta-lactams, and using the same stock concentrations and ratios. Trays were set up in 
accordance with the previous methodology, as were any further steps taken. 
 
 
 
 
 
 
 
1 
4 
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2 
6 5 
Figure 20. Structures of the beta-lactams used during this project. 1, Amoxicillin; 2, 
Ampicillin; 3, Cefotaxime; 4, Cephradine; 5, Oxacillin; 6, Penicillin G. 
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3.3. Results 
As previously stated, the methodology used was identical to the one used in the moenomycin 
section. As such, this results section is to cover the results where the methodology started 
to vary; crystal production with a variety of ligands. 
3.3.1. Crystal Production 
The majority of the crystal trays set up with the beta-lactams failed to produce any crystals. 
However, crystals were formed in wells containing cefotaxime and cephradine. Crystals were 
Figure 21. Crystals formed in the presence of ecoPBP1b/AI167p/cefotaxime. The lack of 
regularity should be noted in these crystal structures. Many of the crystals collected from 
this well were found to be salt crystals. 
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grown in the presence of the novel beta-lactamase CW-019, and further work is being carried 
out with these crystals. 
3.3.2. Diffraction Data sets 
Crystals suspected of containing cefotaxime and cephradine respectively were sent for data 
collection at the Diamond Light Source Synchotron. Whilst a data set was collected for a 
crystal potentially containing cefotaxime, due to the poor resolution of the diffraction data, 
it was decided not to attempt structural solving. The crystals suspected of containing 
cephradine produced diffraction data sets which appeared to be salt crystals as opposed to 
protein crystals. As such, this project produced a structure of ecoPBP1b in complex with one 
beta-lactam; ampicillin. 
3.3.3. 3D modelling of the Penicillin Binding Region 
Using the data collected as part of the moenomycin chapter, the penicillin binding region 
was identified, as well as some potential key amino acid residues. Using the data from King 
et al. (2016), the potential catalytic residues were identified, bond distances measured using 
WinCoot, and modelled in PyMol (figure 22). 
 
Figure 22. Ampicillin (Blue) bound to the transpeptidase binding region of ecoPBP1b. 
Labelled are the amino acids that King et al (2016) identified in their model of PBP1b as 
necessary. Ampicillin binds to a serine residue (Ser474) and is stabilised by 5 other 
residues. These 5 residues varied in distance from 3.05-3.59Å (with the exception of 
Asn677, which was further away, with a distance of 5.18-5.20Å) 
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3.4. Discussion 
3.4.1. ecoPBP1b and Ampicillin 
The model shows ampicillin covalently bound to Ser474 in the penicillin binding region, with 
overlapping residues. The calculated distances support the theory that the other residues 
(Ser536, Asn538, Thr663, Thr665 and Asn667) do not strongly interact with the beta-lactam, 
but rather fold around, enclosing the beta-lactam molecule into a ‘cleft’. Whilst Asn667 is 
considered part of the active site, the distance between it and the ampicillin molecule is 
larger than 4.0Å, indicating that there is no direct interaction. It is possible that Asn667 plays 
an active role in peptidoglycan polymerisation, but is unable to bind to a beta-lactam 
compound. 
Figure 23. Overlaid structures of ecoPBP1B’s transpeptidase domain (active residues 
in red, ampicillin in blue) and 5HL9 (residues in light green, ampicillin in dark green) 
from King et al. (2016). The overall matching is good, with clear similarities, and no 
missing residues. Noted is the residue to the far right (Asn667), which is rotated in 
comparison to the 5HL9 model. 
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Our model with ampicillin corresponds well with the data from King et al, (2016). Overlaying 
the structure of the transpeptidase region shows good overall pairing, as well as the specific 
residues in the active site (Figure 23). One residue that stands out is Asn667, which is 
configured differently to the 5HL9 model. Due to the distance between the residue and the 
ampicillin, its indirect nature (for this substrate) may allow for more direct binding with 
penicillin binding substrates containing different functional groups. Alternatively, it could be 
a redundant conserved residue required for the function of PBPs other than PBP1b, as noted 
by King et al. (2014) who saw involvement with the Asn residue for the PBP3 found in P. 
aeruginosa.   
3.4.2. Beta-Lactam Crystal Production 
It would be useful to understand the alterations caused to the conformation of ecoPBP1b 
with different beta-lactams bound. Whilst structures of ecoPBP1b in complex with ampicillin 
were produced, no other beta-lactam trials reached this stage. ecoPBP1b crystals are 
notoriously hard to collect data sets of, due to their poor diffraction and overall fragility. 
Many crystals have been grown containing a variety of compounds, but due to the poor 
diffraction, it was decided to only use crystals of a certain size for diffraction data collection.  
This contrasts with the previous chapter, where ecoPBP1b crystals in complex with multiple 
ligands had been produced and successfully diffracted at a suitable resolution. This suggests 
that there is issue with the beta-lactams complexing with ecoPBP1b. However, the lower 
number of trials as compared to the previous chapter should be noted, as a larger proportion 
of project time was spent on producing ecoPBP1b/MoeA/Amp complex crystals with 
modified moenomycins. Had an equal amount of time been spent on the beta-lactams 
project, it is probable that sizeable crystals would be produced.  
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3.4.3. Potential Issues with EcoPBP1b as a model for Beta-lactams 
Due to the structural nature of ecoPBP1b, with multiple domains (including one specifically 
designed to penetrate lipid-based membranes), it is not a simple protein to characterise. It 
requires the addition of multiple ligands to stabilise the structure (a moenomycin-based 
compound in the TG domain, as well as a beta-lactam in the TP domain). What has been 
demonstrated is the ability of the TG domain to accommodate ligands with varying structural 
alterations, providing the moenomycin pharmacophore is conserved. This has not yet been 
substantiated with regards to the TP beta-lactam binding site. However, it is unlikely that the 
beta-lactam compounds trialled are of sufficient structural difference to ampicillin as to 
cause major instability. The compounds tested had various side group differences, but all 
contained the conserved beta-lactam ring which comprises the beta-lactam pharmacophore. 
As the compounds used all are currently or have previously been approved in clinical settings 
(in addition to having well documented modes of action), it is unlikely that their attachment 
to the penicillin binding region of the TP domain would have caused significant instability. In 
addition, none of the trials showed significant precipitation early on in the crystallisation 
waiting period, something that had occurred in previous trials when ecoPBP1b wasn’t 
sufficiently stable.  What is more likely is that the addition of other beta-lactams has caused 
conformational shifts which require differing conditions for crystallisation to occur. 
The idea that ecoPBP1b could be used as a model for beta-lactams has not been 
substantiated with this experiment, due to the lack of structures produced. However, 
significant amounts of the groundwork necessary to test this idea has been achieved, with a 
fully functioning methodology for producing ecoPBP1b produced from this project.  
3.4.4. Advantages and Disadvantages of Monofunctional Models 
It may also be worth using a monofunctional transpeptidase (preferentially a cytoplasmically 
accumulated recombinant transpeptidase, which doesn’t have the issues related to 
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membrane-bound transpeptidases) to model the changes in conformation. Such enzymes 
may be simpler to express and characterise, and would still provide an understanding of the 
conformational changes caused by side chain variation in beta-lactams. However, the 
disadvantage of this is the inability to compare the quaternary structures of a bifunctional 
glycosyltransferase, and how it is affected by beta-lactams. Depending on whether future 
projects were based around further understanding ecoPBP1b (or homologues) or more 
based around developing novel beta-lactam based compounds, using a monofunctional 
transpeptidase may be recommended. 
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4. Overall Discussion 
This project has been successful in a variety of ways. Firstly, the confirmation that the MoeA 
conjugates have had no visible alterations to the active site interactions, in conjunction with 
MICs from other research projects, is a good sign for further development of improved 
moenomycin antimicrobials. In addition, it verifies the use of ecoPBP1b as a model for novel 
moenomycin compounds, to test mode of action. In addition, this project has improved the 
methods to obtain useable quantities of ecoPBP1b for further research, especially for X-ray 
crystallography. 
4.1. Improving the Yield of ecoPBP1b crystals 
The utilisation of seeding to dramatically improve the yield of ecoPBP1b crystals can also be 
considered a success. Improving the numbers of suitable crystals increases productivity and 
efficiency, which is useful. It should be taken into account that the crystal seeding did not 
particularly improve the numbers of suitable crystals in the beta-lactam chapter, and there 
is always the risk of overseeding. Overseeding can lead to crowding of the trial wells, and 
prevent crystals from reaching optimum sizes. Whilst not particularly seen in the beta-lactam 
chapter, it was more obviously shown in the MoeA chapter, with 2 wells of 6 being 
overcrowded (leading to a need to seed down a gradient, to produce wells of optimal 
crystals). 
4.2.  ecoPBP1b as a Model for Antimicrobials  
The overall failure to use ecoPBP1b as a model for multiple beta-lactams is an area that 
requires further work. The aim of this project was to produce a variety of structures with 
different beta-lactams bound to the penicillin binding region, in order to look for variations 
in conformation change, highlighting the effects that different residues have. There is the 
potential that the ecoPBP1b/beta-lactam complex may require altered crystallisation 
conditions, with the current conditions preventing proper crystal growth (resulting in the 
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significantly smaller crystals seen in the previous chapter). It is possible to use ecoPBP1b to 
model beta lactams, as demonstrated by King et al. (2016), who characterised ecoPBP1b with 
compounds such as acyl-ampicillin, cephalexin, CENTA, and aztreonam (as part of a wider 
study). This implies that such a model is achievable. It should be noted that the methods 
used by King et al. varied in their crystallisation stage, in which they utilised the sitting drop 
method in addition to differing crystallisation conditions (their mother liquor consisted of 
PEG 3350 (20% w/v), potassium/sodium tartate (0.2M), and Bis Tris (0.1M, pH 8.5), whereas 
the precipitant used in this project was sodium formate (1.22M). Furthermore, the 
concentration of ecoPBP1b used by King et al. was significantly higher than this project 
(20mg/ml as opposed to 12mg/ml).  
Regarding the concentration, this may be due to the detergent required for the sodium 
formate precipitant (in this case, LDAO). Differing detergents may limit the concentration 
that can be achieved. During the process of concentrating after buffer exchange, it was noted 
that a concentration above 13mg/ml caused issues in the crystals produced (warped crystals, 
overprecipitation). It may be worth utilising the sitting drop method in the conditions 
described above in future trials. 
Additionally, the use of detergents is well known to interfere with the detection and 
quantification of purified proteins (Simonian and Smith, 2006). Many detergents, when not 
bound to protein molecules, form micelles in solution, which often absorb light at a 
wavelength of 280nm. This can result in elevated readings, which may cause later issues (if 
the concentration of protein is lower than calculated, then it is less likely that a 
supersaturated solution will be formed during crystal growth trials. 
In order to compete with simpler enzymatic models (the monofunctional TGs and TPs spring 
to mind), issues such as these need to be addressed. At this stage, ecoPBP1b can be used to 
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model novel MoeA analogues well, but improvements are required before it can be used as 
a model for beta-lactams (or other similar classes of antimicrobial). 
4.3. Beta-lactamase Inhibitor Binding 
The beta-lactam chapter also included trials to attempt binding of a novel beta-lactamase 
inhibitor to the transpeptidase domain, in order to determine if it would have the side effect 
of also acting as an antimicrobial agent. As noted in the results of the beta-lactam chapter, 
crystals have been grown in the presence of ecoPBP1b and CW-019, and research is still 
ongoing.  
Beta-lactamase inhibitors tend not to have antimicrobial properties, due to their altered 
structure (many containing significant variations to the beta-lactam core). When the crystal 
trays were set up, ampicillin was replaced with the CW-019, as ampicillin would have 
displaced any CW-019 when competing for the binding site. If CW-019 does not bind to 
ecoPBP1b, then there would be no stabilising compound (the role that ampicillin has). 
Additionally, there is potential that, due to the variation in structure, the conditions used for 
crystallisation may no longer be suitable for the ecoPBP1b/CW-019 crystal complex to grow. 
It should be noted that it was expected that CW-019 wouldn’t bind to ecoPBP1b, but due to 
its similar structure to the beta-lactam core there was a possibility it would bind (similar to 
CENTA, as done by King et al. (2016)). However, due to the current lack of structures with 
other beta-lactams (which have been identified to bind to similar PBPs), it cannot be 
determined whether CW-019 is unable to bind entirely. It would be interesting to see 
whether the compound on its own would have inhibitory properties, as well as testing it with 
a clinical beta-lactam compound on a strain of bacteria with a beta-lactamase production 
gene. This could be carried out with preliminary MIC testing using 96 well plates.  
 Again, linking back to the King et al. study, they managed to bind a beta-lactamase substrate 
(CENTA) to the penicillin-binding region of ecoPBP1b. This indicates that in the right 
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circumstances, a beta-lactamase inhibitor may be seen to bind to the penicillin-binding 
region of the TP domain. Structurally, CW-019 does not actually contain a beta-lactam ring, 
which may prevent the binding to the TP domain. In addition, CENTA is a substrate, not an 
inhibitor. As beta-lactamases are designed to degrade the beta-lactam ring, it would be 
logical that that CENTA is capable of binding to the TP domain. Despite it not binding to the 
TP domain, CW-019 may still have beta-lactamase inhibitory effects, capable of being used 
in conjunction with beta-lactams on resistant bacterial species. 
Further research would be useful into the production of novel moenomycin inhibitors, 
especially those containing peptide linkers. As demonstrated by this project, this is an area 
with significant potential for antimicrobial design. In addition, the design of such inhibitors 
with the ability to inhibit both beta-lactams and beta-lactamases (building on any findings 
from the CW-019 research) would be another point of research 
4.4. Antimicrobial Resistance 
The wider issues of antimicrobial resistance is an issue that is going to continue regardless of 
the number of antimicrobial compounds produced. As long as antibiotics have widespread 
use (and in many cases, improper use), bacterial species will develop resistance. There is no 
so-called ‘golden bullet’ when it comes to infectious diseases. Bacterial species have been 
prevalent since the start of life on Earth, and their ability to adapt to all kinds of 
environmental change has been key in their survival. Every antibiotic in clinical use has seen 
some level of resistance develop, including those of a ‘last line’ nature; vancomycin and 
erythromycin, for example. Wider initiatives are required to reduce usage of antibiotic 
compounds both clinically and commercially. It is understood that such changes would not 
be immediate, but should be effected at some level. Resistance to such changes (both from 
medical, veterinary and agricultural professionals as well as pharmaceutical companies) 
should be expected, which will limit any widespread change.   
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Development of novel beta-lactams is an area of research that has been up for debate, with 
many research groups struggling to produce compounds with significant differences and 
lessened resistance. Research into this area may be better focussed on producing 
compounds to be used in conjunction with currently clinically approved beta lactams, such 
as the aforementioned beta lactamase inhibitors. Whilst this would provide some longevity 
to our current armoury of beta lactams, this would eventually stagnate in much the same 
way that beta-lactam research failed to progress. Due to the multiple areas of resistance to 
these classes of antibiotics, this would eventually select for methods of resistance which are 
harder to overcome (altered PBPs, for example). In addition, it has been noted that many 
beta lactamase inhibitors are not particularly broad spectrum towards beta-lactamases, 
which limits their clinical applications (resistant infections would require genomic analysis to 
determine which BLase inhibitors to use in conjunction with beta lactam therapy) (Bush, 
2015). 
 In an ideal situation, development would be best focussed on antibiotics with novel modes 
of action. Advances have been made in the last couple of years looking at identifying and 
characterising new compounds, such as the iChip, publicised in 2015 alongside the 
identification of a novel compound: Teixobactin (Ling et al. 2015). 
4.5. Teixobactin; the Next Antibiotic Goldmine? 
Teixobactin is known to bind to lipid II, a major precursor to peptidoglycan utilised by 
glycosyltransferases such as ecoPBP1b. Currently, it is only known that teixobactin prevents 
lipid II from binding to the transglycosylases that use it as a substrate. However it could be 
suggested that the teixobactin/Lipid II complex formed may additionally inhibit 
transglycosylases. As of yet, no such complex has been formed bound to a transglycosylase. 
If such a complex could be produced, it would add a second layer to the mode of action of 
teixobactin, improving the understanding of this novel compound. 
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Interest has been high in teixobactin, especially developing analogues to the naturally 
occurring compound. This is due to the incredibly low levels of resistance demonstrated in 
preliminary resistance testing. It is expected that resistance to teixobactin will eventually 
develop (especially in clinical settings), as has developed with all other major antibiotic 
compounds. However, this resistance is likely to be low level, and have a high energy cost. 
As mentioned, teixobactin binds to a highly conserved, essential substrate (lipid II). Alteration 
of this essential substrate is unlikely to occur, as it would also require the alterations to occur 
in the enzymes which utilise Lipid II. It is more likely that the first resistance seen will be in 
laboratory testing, with short-lived changes with high energy costs. 
It may also be recommended that teixobactin is kept as a ‘last resort’ antibiotic, to prevent 
widespread usage and subsequent widespread resistance developing. Other methods to 
limit resistance development to teixobactin is to use it in conjunction with other compounds 
(as part of combination therapy), a method which has seen a decrease in resistance 
occurring. 
Novel compounds (such as teixobactin) should not be hailed as new golden bullets. Instead, 
they should be seen for what they are; the next line of defence against an unstoppable force. 
These compounds will simply buy time until the following line of defence can be identified, 
be it another naturally occurring antibiotic, or a completely fresh style of antimicrobial 
entirely. Complacency, and imagined security in current compounds has brought us to this 
stage, and it is up to us to prevent it from occurring to this level again.  
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5. Conclusions 
It is clear that novel antimicrobials are required in order to sustain the current standard of 
healthcare in most countries. The current approach to novel antimicrobial design (modifying 
existing families of compounds), by itself, may eventually see a decline in the numbers of 
useful compounds approached. Prolonging this approach may require both looking 
backwards (at compounds that were discarded as poor alternatives during the ‘golden age’ 
of antimicrobial discovery), as well as looking forwards, not just identifying new compounds, 
but designing new methods for locating them. 
In the interim, more study needs to be carried out on ecoPBP1b and the role it can play as 
an antimicrobial target. Whilst the current understanding of ecoPBP1b is suitable for 
moenomycin analogues, it may be worth looking at other conditions to crystallise ecoPBP1b 
in complex with larger beta-lactams than ampicillin. 
This study has improved upon the conditions necessary to produce useable quantities of 
ecoPBP1B for further studies, especially in those involving crystallisation. In addition, this 
project has highlighted the fact that ecoPBP1b can be used to explore novel alterations to 
current antimicrobials – specifically the moenomycins and beta-lactams, and improve the 
design of novel inhibitors such as CW-019. This will facilitate further generations of 
antimicrobials compounds to help in the fight against antimicrobial resistance. 
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